Background The successful diffusion of new drugs is crucial for both pharmaceutical
companies and patients—and of wider stakeholder concern, including for the funding of …

Background New drugs often substitute others cheaper and with a risk-benefit balance
better established. Our aim was to analyse the diffusion of new drugs during the first months …

Objectives. There is a large variation in implementing research findings in clinical practice.
We examined whether the concept of early or late adopters is universal for the diffusion of all …

Background Implementation and uptake of novel and cost-effective medicines can improve
patient health outcomes and healthcare efficiency. However, the uptake of new medicines …

Summary Background and Objective: The rate of uptake of new medicines in the UK is
slower than in many other OECD countries. The majority of new medicines are introduced …

Background and objective: The uptake of new medicines is slower in the UK than in many
other countries. Previous research found that cost and price have little influence on general …

Abstract Background In 2007, Alberta became the first Canadian jurisdiction to grant
pharmacists a wide range of prescribing privileges. Our objective was to understand what …

Objective: To explore what is known about organizational processes that determine whether
(and the extent and rate at which) new non-pharmaceutical technologies are adopted and …

The Managed Introduction of New Medicines Ljubljana, Slovenia, 19–21 March 2012 The 3-
day course on the managed entry of new medicines was run by the Piperska group, which is …

Introduction With an increase in prescription drug spending and rising drug costs there is a
need to encourage the use of generic prescription drugs. However, maximizing generic drug …